This research project is testing a potential new treatment called Cannabidiol (CBD) for helping people with symptoms that might indicate risk of a psychotic disorder (UHR symptoms). CBD is a non-psychoactive treatment, meaning it does not you a ‘high’.
UHR symptoms vary for individuals, but can include feeling low in mood, feeling paranoid or seeing or hearing things that they know aren’t there. Some people might worry their thoughts are being heard, may not feel right in themselves, or have more difficulty than usual coping with work, school or relationships.
Anticipated date that enrolment will close: October 2025
Erythropoietic Protoporphyria is a lifelong condition characterised by painful skin when exposed to bright sunlight.
The medication we are testing for this study is Bitopertin (DISC-1459) and is given as an oral tablet. Bitopertin has already been given to over 4,000 individuals in clinical trials for other conditions.
The purpose of this research project is to measure how safe and effective this medication is in treating participants with Erythropoietic Protoporphyria. This study aims to understand the medication’s effect on underlying mechanisms that trigger sunlight intolerance. The outcome of this project could support new treatments to increase quality of life in people with Porphyria.
Anticipated Date Enrolment will close: 31 October 2022